GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Reviva Pharmaceuticals
Reviva Pharmaceuticals is a biotech company developing drugs for the treatment of central nervous system diseases. Its stock price is highly volatile and dependent on clinical trial results. The chart reflects the binary risks and hopes inherent in the sector.
Share prices of companies in the market segment - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. We've categorized it under "Neurology." The chart below reflects how investors assess the risks and prospects in this complex field.
Broad Market Index - GURU.Markets
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and depression. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
RVPH - Daily change in the company's share price Reviva Pharmaceuticals
For Reviva Pharmaceuticals Holdings, Inc., a company focused on neuropsychiatry, daily price change is a measure of its enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Reviva Pharmaceuticals Holdings, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with RVPH, which focuses on CNS diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Reviva Pharmaceuticals is a biotech company specializing in the treatment of diseases of the central nervous system. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Reviva Pharmaceuticals
Reviva Pharmaceuticals' year-to-date performance is a story of drug development for the treatment of central nervous system disorders. Its 12-month market cap depends entirely on the clinical trial data for its lead candidate for schizophrenia. Success or failure in key studies will have a dramatic impact on its future.
Annual dynamics of market capitalization of the market segment - Neuro
As an early-stage biotech, Reviva is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Reviva Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its key drugs is a binary outcome event for its stock.
Monthly dynamics of market capitalization of the market segment - Neuro
Reviva Pharmaceuticals develops drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. This is one of the most complex and risky areas in pharmaceuticals. The dynamics of the biotech sector reflect the hopes for breakthroughs. Reviva's story is an attempt to create a medicine that could change the lives of millions of patients and their families.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Reviva Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to understand how its potential for treating schizophrenia and other disorders has impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Reviva Pharmaceuticals
Reviva Pharmaceuticals is a biotech company developing drugs for the treatment of central nervous system diseases. Its weekly stock price is highly volatile and depends on news about clinical trials, where the stakes are high due to the complexity of these diseases and the binary nature of their outcomes.
Weekly dynamics of market capitalization of the market segment - Neuro
Reviva Pharmaceuticals is a biotech company developing drugs for the treatment of central nervous system diseases. Its weekly stock price is highly volatile and depends on news about clinical trials, where the stakes are high due to the complexity of these diseases and the binary nature of their outcomes.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Reviva, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
RVPH - Market capitalization of the company Reviva Pharmaceuticals
Reviva Pharmaceuticals' market capitalization chart is a biotech play focused on developing drugs to treat central nervous system disorders, such as schizophrenia. Its volatile chart is a classic "roller coaster" reflecting investor reactions to clinical trial data.
RVPH - Share of the company's market capitalization Reviva Pharmaceuticals within the market segment - Neuro
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Its market capitalization reflects the potential of its leading candidates. The chart below demonstrates the high volatility associated with clinical trial results.
Market capitalization of the market segment - Neuro
Reviva Pharmaceuticals develops drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. The chart below shows the overall market capitalization of the neuroscience sector. It reflects the enormous risks and potential rewards in this highly complex field of medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
The fight against schizophrenia and Parkinson's disease is illustrated here. Reviva Pharmaceuticals develops drugs for the treatment of complex neuropsychiatric disorders. Its volatile pipeline reflects all the risks and hopes associated with clinical trials in this complex area.
Book value capitalization of the company, segment and market as a whole
RVPH - Book value capitalization of the company Reviva Pharmaceuticals
Reviva Pharmaceuticals' book value is derived from its intellectual property for drugs treating central nervous system disorders and its financial reserves. This is its scientific capital. The chart shows how the biotech company manages its budget for late-stage clinical trials of its lead candidates.
RVPH - Share of the company's book capitalization Reviva Pharmaceuticals within the market segment - Neuro
Reviva Pharmaceuticals is a biotechnology company developing drugs for the treatment of central nervous system diseases. Its assets are intellectual property. The chart shows a minimal share of physical assets, which is typical for an R&D company.
Market segment balance sheet capitalization - Neuro
The BCap_Ges chart for biotechnology clearly demonstrates that this industry competes not on the size of its plants, but on the speed of discovery. Reviva Pharmaceuticals is a shining example of this science-intensive world. Its business model is not based on building production facilities, but on investing capital in the most expensive and risky stage—clinical trials of CNS drugs—which is its main asset.
Book value of all companies included in the broad market index - GURU.Markets
Reviva Pharmaceuticals' book value is capital allocated to clinical trials of drugs for the treatment of central nervous system disorders, such as schizophrenia. It reflects the financial foundation that allows the company to develop tangible drugs for complex mental disorders.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Reviva Pharmaceuticals
Reviva Pharmaceuticals develops drugs to treat central nervous system disorders. It's a biotech company, and its market capitalization is a bet on science. The MvsBCap chart will reflect all the risks and hopes associated with developing drugs for complex diseases like schizophrenia and Alzheimer's.
Market to book capitalization ratio in a market segment - Neuro
Reviva Pharmaceuticals develops drugs to treat diseases of the central nervous system. Its value is entirely dependent on the success of its clinical trials. The chart reflects investor expectations for the future of its portfolio.
Market to book capitalization ratio for the market as a whole
Reviva Pharmaceuticals develops drugs for the treatment of central nervous system disorders. The company's valuation reflects investors' bet on the success of its clinical trials. Book value is irrelevant compared to the potential market size for its drugs if approved.
Debts of the company, segment and market as a whole
RVPH - Company debts Reviva Pharmaceuticals
Reviva, a clinical-stage biopharmaceutical company developing drugs for diseases of the central nervous system, relies entirely on external funding. This chart shows how the company manages its limited resources to advance its candidates through the costly and time-consuming stages of clinical trials.
Market segment debts - Neuro
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Funding long and complex trials in this area is a key challenge. The chart shows how the company manages its capital to bring its potential drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Reviva Pharmaceuticals
Reviva Pharmaceuticals develops drugs to treat diseases of the central nervous system. This chart shows its high reliance on debt to finance lengthy and expensive clinical trials. High debt in this industry is a huge bet on scientific success, which will either lead to a breakthrough or lead to ruin.
Market segment debt to market segment book capitalization - Neuro
Reviva Pharmaceuticals is a clinical-stage company developing drugs for the treatment of central nervous system disorders. The chart shows the sector's debt burden, helping to understand how the company finances its long-term, high-risk research in one of the most complex areas of medicine.
Debt to book value of all companies in the market
Reviva Pharmaceuticals Holdings develops drugs for the treatment of central nervous system diseases. For a clinical-stage biotech company, the overall financial situation, reflected in this chart, is of paramount importance. It determines the ability to attract the capital necessary to conduct expensive and lengthy clinical trials.
P/E of the company, segment and market as a whole
P/E - Reviva Pharmaceuticals
This chart of Reviva Pharmaceuticals, a company developing drugs for central nervous system disorders, shows how investors view its scientific potential. The trend reflects expectations for the success of its schizophrenia and depression drugs in clinical trials, which could open up a multibillion-dollar market for the company.
P/E of the market segment - Neuro
This chart shows the average P/E for the biopharmaceutical industry in which Reviva is developing. The high average valuation of the sector reflects the potential for new drugs. The chart illustrates this general context against which investors evaluate Reviva's scientific developments and prospects in neuroscience.
P/E of the market as a whole
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. This chart shows risk appetite in biotech. It helps understand how the market views Reviva's chances of success in these extremely complex and risky areas, where many large companies have failed.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Reviva Pharmaceuticals
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. This chart shows analysts' confidence that its drug candidates will be successful in clinical trials and find their niche in the market.
%20P%2FE%20Reviva%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Reviva-Pharmaceuticals&v=1772513735866 "Chart of the company's future (projected) P/E Reviva Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Reviva Pharmaceuticals is a clinical-stage company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. This chart displays its future profitability expectations, allowing us to assess how the market perceives its scientific approach to treating these complex disorders.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513735867 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Reviva Pharmaceuticals is a clinical-stage company developing drugs for the treatment of central nervous system disorders. Its value reflects expectations of future success. This chart, reflecting the market's risk appetite, shows how willing investors are to wait for results. During periods of optimism, funding for such projects is more readily available.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513735868 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings develops drugs to treat diseases of the central nervous system. Its financial position is determined by the costs of clinical trials. This chart shows how much capital is burned in the process of developing new drugs to treat complex conditions such as schizophrenia and Alzheimer's disease.
Profit of companies in the market segment - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Its lead candidate targets schizophrenia and other neuropsychiatric disorders. This graph reflects the high risk and potential of the neuroscience sector, where the development of a safe and effective antipsychotic could be a multi-billion dollar success.
Overall market profit
Reviva Pharmaceuticals develops drugs to treat diseases of the central nervous system. This is a lengthy and expensive process. The availability of capital to finance clinical trials depends on financial market sentiment, which, in turn, correlates with the overall state of the economy, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Reviva Pharmaceuticals
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. This chart represents a consolidated analyst forecast, betting on the success of its clinical programs in these complex but potentially enormous markets.
%20profit%20of%20the%20company%20Reviva%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Reviva-Pharmaceuticals&v=1772513735886 "Graph of future (projected) profit of the company Reviva Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Reviva Pharmaceuticals is a clinical-stage biotechnology company developing drugs for the treatment of central nervous system disorders such as schizophrenia and Alzheimer's disease. Its lead candidate has a unique mechanism of action. This chart shows profitability projections for the biotech sector, reflecting the urgent need for new, more effective treatments for mental disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513735897 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Reviva Pharmaceuticals Holdings develops drugs to treat diseases of the central nervous system. Like many biotech companies, its future depends on the results of clinical trials and its ability to raise capital. This schedule, reflecting general profitability expectations, influences investor risk appetite, which determines the financing of such projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513735901 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Reviva Pharmaceuticals
Reviva Pharmaceuticals develops drugs to treat diseases of the central nervous system. This chart shows its estimated scientific potential. Its high valuation reflects investors' hopes that its drugs will be successful in treating complex neurological and psychiatric disorders.
P/S market segment - Neuro
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company developing drugs to treat diseases of the central nervous system. This chart shows the average revenue estimate in the biotech sector. It provides an indication of how highly investors value the potential revenue from Reviva's drug candidates targeting conditions such as schizophrenia.
P/S of the market as a whole
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. Their success depends on clinical data. This chart provides a general revenue metric that can be used to assess how the market values biotech companies working in the complex field of neuroscience.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Reviva Pharmaceuticals
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders, such as schizophrenia and Alzheimer's disease. This chart reflects market expectations for its clinical programs. The assessment is based on the potential of its candidates to offer new, safer, and more effective treatments.
%20P%2FS%20Reviva%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Reviva-Pharmaceuticals&v=1772513735988 "The graph of the company's future (projected) P/S Reviva Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Parkinson's disease. This chart shows how the market values its portfolio relative to the neuroscience sector.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513736001 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in diseases of the central nervous system. This chart, reflecting overall investor risk appetite, is critical for Reviva. Market optimism allows companies like this to more easily raise capital for costly clinical trials in one of the most complex areas of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513736016 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat central nervous system disorders such as schizophrenia and Alzheimer's disease. This chart reflects research funding, not commercial revenue. It illustrates investments in the discovery of new treatments for complex mental and neurological disorders.
Sales of companies in the market segment - Neuro
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company developing drugs for the treatment of diseases of the central nervous system. Its activities are segmented into various drug candidate development programs. This chart depicts the cash flows associated with its lead drug, demonstrating its clinical and commercial potential.
Overall market sales
Reviva Pharmaceuticals is a pharmaceutical company developing drugs for the treatment of central nervous system disorders. Its success depends on progress in clinical trials. The company is working on drugs for complex conditions such as schizophrenia and Alzheimer's disease, where the need for new, effective treatments is extremely high.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as schizophrenia and Alzheimer's disease. Its future sales forecast is based on the expected success of its key candidates in clinical trials.
%20sales%20of%20the%20company%20Reviva%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Reviva-Pharmaceuticals&v=1772513736034 "Schedule of future (projected) sales of the company Reviva Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders. This chart reflects expectations for the entire neuroscience sector. It helps assess analysts' forecasts for demand for new treatments for schizophrenia and other mental disorders.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513736044 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Reviva Pharmaceuticals, a company developing drugs for the treatment of central nervous system diseases, depends on the biotech market for its research funding. This chart of overall sales forecasts reflects overall economic confidence, which influences investor willingness to invest in risky projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513736047 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders such as schizophrenia and Alzheimer's disease. This chart reflects its financial position, where high costs for lengthy and expensive clinical trials are key to future success.
Market segment marginality - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Operational efficiency in this complex and risky field lies in conducting research as cost-effectively as possible. The chart shows how the company manages its resources in the race for a breakthrough drug.
Market marginality as a whole
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Its success depends on clinical trial results and regulatory approval. This chart shows average profitability, but for RVPH, value is created through scientific innovation in the complex and risky field of neuroscience.
Employees in the company, segment and market as a whole
Number of employees in the company Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage pharmaceutical company specializing in CNS diseases. This diagram shows a small team managing the development process. This compact structure is typical for biotechs that raise capital to fund research through contractors.
Share of the company's employees Reviva Pharmaceuticals within the market segment - Neuro
Reviva Pharmaceuticals develops drugs to treat diseases of the central nervous system. Neurology is an extremely complex field. This reflects its investment in research that could lead to breakthroughs in the treatment of psychiatric and neurological disorders.
Number of employees in the market segment - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs to treat diseases of the central nervous system. This chart shows employment in the neuroscience sector. The growing number of neuroscientists indicates a high need for new treatments for conditions such as schizophrenia and Alzheimer's disease, which are Reviva's focus.
Number of employees in the market as a whole
Reviva Pharmaceuticals develops drugs for the treatment of central nervous system diseases. Biotechnology is an industry with a long development cycle. This graph illustrates the current situation, but for Reviva, successful completion of multi-year clinical trials, which will determine its future, is far more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals Holdings, Inc. develops drugs to treat diseases of the central nervous system. This chart likely shows a high market capitalization per employee. This reflects the market's assessment of the potential of its developments, which could reach a multibillion-dollar market, rather than current assets or staff.
%20of%20the%20company%20Reviva%20Pharmaceuticals%20(RVPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Reviva-Pharmaceuticals-RVPH&v=1772513736131 "Chart of market capitalization per employee (in thousands of dollars) of the company Reviva Pharmaceuticals (RVPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Reviva Pharmaceuticals Holdings, Inc. develops drugs for the treatment of diseases of the central nervous system. In this complex area of biopharma, the cost per employee is a market assessment of scientific potential and the prospects of clinical trials. It is an indicator of the value of their research team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513736145 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Reviva Pharmaceuticals is a biotech company developing drugs to treat diseases of the central nervous system. The chart shows the market's speculative assessment of the potential of its research in the complex field of neurology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513736159 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals (RVPH) is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system (CNS) disorders such as schizophrenia and depression. This negative graph shows R&D intensity. It measures how much capital the company "burns" per scientist to advance its candidates through complex and lengthy clinical trials.
%20Chart%20Reviva%20Pharmaceuticals%20(RVPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Reviva-Pharmaceuticals-RVPH&v=1772513736175 "Company Profit Per Employee (in thousands of dollars) Chart Reviva Pharmaceuticals (RVPH)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Success in this complex field depends on the effectiveness of its team of scientists and clinicians. This chart shows the financial return on their work and serves as a comparison with other companies working in the neuroscience field.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513736199 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Reviva Pharmaceuticals (RVPH) is a biotech company developing drugs for the treatment of central nervous system disorders (schizophrenia). It is a clinical-stage R&D company. Negative profit per employee is the norm. The graph shows the "cost" of a team of scientists working on this complex problem.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513736226 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders. It has no commercial revenue. This graph is an indicator of future potential that could be realized if clinical trials are successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Reviva-Pharmaceuticals-RVPH&v=1772513736240 "Sales chart per company employee Reviva Pharmaceuticals (RVPH)")
Sales per employee in the market segment - Neuro
Reviva Pharmaceuticals is a biopharmaceutical company focused on CNS drugs (schizophrenia, Parkinson's disease). This chart compares revenue per employee (R&D) to the industry average. It reflects how productive their scientific platform is in attracting partner funding and driving development.
Sales per employee for the market as a whole
Reviva Pharmaceuticals (RVPH) is a clinical-stage biotech company developing drugs for the treatment of central nervous system disorders (schizophrenia, ADHD). The company has no commercial sales revenue. This graph will show $0, which is typical for R&D companies whose research staff is focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals (RVPH) is a biotech company working in the highly complex field of neuroscience (schizophrenia, Alzheimer's). It's a "graveyard" for pharmaceutical companies. This chart shows the number of investors betting that the company's drugs will fail in clinical trials, like so many before them.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Reviva-Pharmaceuticals-RVPH&v=1772513736288 "Short Shares Chart for the Company Reviva Pharmaceuticals (RVPH)")
Shares shorted by market segment - Neuro
Reviva Pharmaceuticals (RVPH) is a biopharmaceutical company specializing in CNS diseases. Their lead candidate is a drug for the treatment of schizophrenia and other psychoses. This chart shows the bets against the "neurological biotech" sector, reflecting investor doubts about the success of clinical trials in this highly complex field.
Shares shorted by the overall market
Reviva Pharmaceuticals develops drugs to treat central nervous system disorders such as schizophrenia and depression. These are huge markets, but with the highest risk of clinical trial failure. This chart measures overall fear. When investors are afraid, they are unwilling to bet on binary outcomes. A failed RVPH trial would wipe out the stock, and this risk seems too great in a volatile market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Reviva Pharmaceuticals (RVPH)
Reviva Pharmaceuticals (RVPH) develops treatments for central nervous system disorders such as schizophrenia. It's a biotech whose value depends on the success of its research. This chart measures price momentum. It helps you see when investor enthusiasm (above 70) for the trial is becoming excessive or when the sell-off (below 30) is going too far.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Reviva-Pharmaceuticals-RVPH&v=1772513736345 "RSI 14 indicator chart for the company's stock Reviva Pharmaceuticals (RVPH)")
RSI 14 Market Segment - Neuro
Reviva (RVPH) is a biotech company targeting the most challenging targets: central nervous system (CNS) diseases such as schizophrenia and depression. This chart measures the "manic-depressive" pulse of the entire Neuroscience sector. It shows when the entire industry is overheated by expectations of a breakthrough or oversold by news of yet another setback.
RSI 14 for the overall market
Reviva (RVPH) is a biotech company. Like everything in its sector, it's critically dependent on this curve. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RVPH (Reviva Pharmaceuticals)
Reviva (RVPH) is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders (schizophrenia, Alzheimer's, and depression). This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RVPH-Reviva-Pharmaceuticals&v=1772513736424 "A chart showing analyst consensus forecasts for the expected stock price. RVPH (Reviva Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price RVPH (Reviva Pharmaceuticals)
Reviva Pharmaceuticals is a biotech company developing drugs for the treatment of central nervous system disorders, particularly schizophrenia. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their R&D pipeline and the chances of success in this challenging therapeutic area.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RVPH-Reviva-Pharmaceuticals&v=1772513736426 "A chart showing the difference between the consensus forecast and the actual stock price. RVPH (Reviva Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Reviva (RVPH) is a biopharmaceutical company developing drugs (Brilaridine) for the treatment of mental disorders (schizophrenia) and neurological diseases (Alzheimer's, Parkinson's). This chart shows general expectations for the neuroscience sector. It reflects whether experts believe R&D breakthroughs in the treatment of brain diseases are possible.
Analysts' consensus forecast for the overall market share price
Reviva Pharmaceuticals (RVPH) is a clinical-stage biopharmaceutical company focused on treating psychiatric (schizophrenia) and neurological disorders. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D projects in one of the most complex and risky areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage biotech focused on challenging targets in the CNS (central nervous system). Their drug candidates target schizophrenia, depression, and Alzheimer's disease. This chart is a clear indicator of their (very risky) R&D. Its dynamics depend entirely on their clinical data and their chances of achieving a breakthrough in brain treatment.
AKIMA Market Segment Index - Neuro
Reviva Pharmaceuticals (RVPH) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Their lead candidate, Bralaneltin, is aimed at treating schizophrenia and other neuropsychiatric disorders. The chart shows the average index for the segment, helping investors assess how RVPH's risks in the complex field of neuroscience compare to the average.
The AKIM Index for the overall market
Reviva Pharmaceuticals is a company developing new treatments for central nervous system disorders (schizophrenia) and respiratory diseases. Its key asset is Brilaroxazine. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this late-stage clinical research project compares to overall economic trends.
